Applied Therapeutics is laying off 46% of its workforce to conserve cash while its board explores M&A, partnerships, licensing, or other strategic options. The review has no set deadline and may not result in a deal. The company also plans to meet the FDA to finalise the design of its late-stage Govorestat study for SORD deficiency.